">
Lotte Biologics has ambitious plans for its antibody-drug conjugate and contract development and manufacturing organization businesses.
Lotte Biologics tapped James Park, former CEO of GC Cell, as its new leader on Monday, with an aim to expand its global market presence.
Lotte is looking toward more industry innovation with the proactive adoption of AI across the group’s array of businesses. The intent is to go beyond enhancing efficiency to strengthen corporate competitive advantage. Moreover, Lotte is preparing...
Lotte Biologics began construction on its 360,000-liter production site in Songdo, Incheon.
Lotte Corporation will funnel 120 billion won ($86.4 million) into Lotte Biologics for the biopharmaceutical contract manufacturer’s upcoming production plant in Incheon.
Lotte Biologics and Merck, a German chemical and technology giant, signed an agreement for a strategic collaboration in biomanufacturing.
With the global life science industry’s eyes set on San Francisco, Korea’s emerging or rising biopharma companies gathered in the Bay area to join the annual J.P. Morgan Healthcare Conference.
Samsung Biologics has filed another police report against departing employees set to join Lotte Biologics, alleging trade secret infringement.
BARCELONA, Spain — Lotte Biologics, a biopharmaceutical contract manufacturer, aims to go public by around 2027 to 2028, according to its CEO.
Samsung Biologics is eyeing new opportunities in Barcelona as it showcases its fifth plant at the CPHI Worldwide 2023 event, the world's largest pharmaceutical trade show.
Korea JoongAng Daily Sitemap